TerminatedPHASE1, PHASE2NCT01640301
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Studying Therapy related acute myeloid leukemia and myelodysplastic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Aude ChapuisFred Hutch/University of Washington Cancer Consortium
- Intervention
- Aldesleukin(biological)
- Enrollment
- 47 enrolled
- Eligibility
- All sexes
- Timeline
- 2012 – 2020
Study locations (1)
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01640301 on ClinicalTrials.gov